Trial Profile
Open label two treatment half-side comparative study to analyse difference in nasal bioavailability between MP29-02 and fluticasone propionate
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2021
Price :
$35
*
At a glance
- Drugs Azelastine/fluticasone-propionate (Primary) ; Fluticasone propionate
- Indications Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis
- Focus Pharmacokinetics
- Acronyms BIODYMF
- 09 Aug 2021 This trial has been completed (End Date: 25 Feb 2019), according to European Clinical Trials Database record.
- 07 Jul 2021 Planned End Date changed from 1 Dec 2017 to 1 Mar 2020.
- 07 Jul 2021 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2020.